HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients

Psychoneuroendocrinology

Volumn 34, Issue 1, 2009, Pages 99-109

  Binder, E B ^a   Kunzel H E ^a   Nickel, T ^a   Kern, N ^a   Pfennig, A ^a   Majer, M ^a   Uhr, M ^a   Ising, M ^a   Holsboer, F ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Depression; Dex CRH test; Gender; HPA axis

Indexed keywords

BENZODIAZEPINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; HYDROCORTISONE; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DISEASE SEVERITY; ESTRADIOL BLOOD LEVEL; FEMALE; HAMILTON SCALE; HOSPITAL ADMISSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; MALE; POSTMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; REMISSION; SEX DIFFERENCE; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADRENOCORTICOTROPIC HORMONE; ANTIDEPRESSIVE AGENTS; CORTICOTROPIN-RELEASING HORMONE; DEPRESSIVE DISORDER, MAJOR; DEXAMETHASONE; FEMALE; FOLLICLE STIMULATING HORMONE; GONADAL STEROID HORMONES; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; PSYCHIATRIC STATUS RATING SCALES; SEX CHARACTERISTICS; TREATMENT OUTCOME;

EID: 57749180641     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2008.08.018     Document Type: Article

References (79)

1. Aihara M., Ida I., Yuuki N., Oshima A., Kumano H., Takahashi K., Fukuda M., Oriuchi N., Endo K., Matsuda H., and Mikuni M. HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Res. 155 3 (2007) 245-256
2. Altemus M., Redwine L., Leong Y.M., Yoshikawa T., Yehuda R., Detera-Wadleigh S., and Murphy D.L. Reduced sensitivity to glucocorticoid feedback and reduced glucocorticoid receptor mRNA expression in the luteal phase of the menstrual cycle. Neuropsychopharmacology 17 2 (1997) 100-109
3. Bao A.M., Hestiantoro A., Van Someren E.J., Swaab D.F., and Zhou J.N. Colocalization of corticotropin-releasing hormone and oestrogen receptor-alpha in the paraventricular nucleus of the hypothalamus in mood disorders. Brain 128 Pt 6 (2005) 1301-1313
4. Binder E.B., Salyakina D., Lichtner P., Wochnik G.M., Ising M., Putz B., Papiol S., Seaman S., Lucae S., Kohli M.A., Nickel T., Kunzel H.E., Fuchs B., Majer M., Pfennig A., Kern N., Brunner J., Modell S., Baghai T., Deiml T., Zill P., Bondy B., Rupprecht R., Messer T., Kohnlein O., Dabitz H., Bruckl T., Muller N., Pfister H., Lieb R., Mueller J.C., Lohmussaar E., Strom T.M., Bettecken T., Meitinger T., Uhr M., Rein T., Holsboer F., and Muller-Myhsok B. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 36 12 (2004) 1319-1325
5. Burgess L.H., and Handa R.J. Chronic estrogen-induced alterations in adrenocorticotropin and corticosterone secretion, and glucocorticoid receptor-mediated functions in female rats. Endocrinology 131 3 (1992) 1261-1269
6. Dawood T., Williams M.R., Fullerton M.J., Myles K., Schuijers J., Funder J.W., Sudhir K., and Komesaroff P.A. Glucocorticoid responses to stress in castrate and testosterone-replaced rams. Regul. Pept. 125 1-3 (2005) 47-53
7. de Kloet E.R., Joels M., and Holsboer F. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 6 6 (2005) 463-475
8. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
9. Heim C., Mletzko T., Purselle D., Musselman D.L., and Nemeroff C.B. The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma. Biol. Psychiatry 63 4 (2008) 398-405
10. Heim C., Plotsky P.M., and Nemeroff C.B. Importance of studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology 29 4 (2004) 641-648
11. Heuser I., Yassouridis A., and Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J. Psychiatr. Res. 28 4 (1994) 341-356
12. Heuser I.J., Gotthardt U., Schweiger U., Schmider J., Lammers C.H., Dettling M., and Holsboer F. Age-associated changes of pituitary-adrenocortical hormone regulation in humans: importance of gender. Neurobiol. Aging 15 2 (1994) 227-231
13. Heuser I.J., Schweiger U., Gotthardt U., Schmider J., Lammers C.H., Dettling M., Yassouridis A., and Holsboer F. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am. J. Psychiatry 153 1 (1996) 93-99
14. Holsboer-Trachsler E., Stohler R., and Hatzinger M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Res. 38 2 (1991) 163-171
15. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23 5 (2000) 477-501
16. Holsboer F., von Bardeleben U., Wiedemann K., Muller O.A., and Stalla G.K. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression Implications for pathophysiology of DST nonsuppression. Biol. Psychiatry 22 2 (1987) 228-234
17. Horstmann, S., Dose, T., Lucae, S., Kloiber, S., Menke, A., Hennings, J., Spieler, D., Uhr, M., Holsboer, F., Ising, M., 2008. Suppressive effect of mirtazapine on the HPA system in acutely depressed women seems to be transient and not related to antidepressant action, Psychoneuroendocrinology, in press.
18. Hubler T.R., and Scammell J.G. Intronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids. Cell Stress Chaperones 9 3 (2004) 243-252
19. Ising M., Horstmann S., Kloiber S., Lucae S., Binder E.B., Kern N., Kunzel H.E., Pfennig A., Uhr M., and Holsboer F. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression: a potential biomarker?. Biol. Psychiatry 62 1 (2007) 47-54
20. Ising M., Kunzel H.E., Binder E.B., Nickel T., Modell S., and Holsboer F. The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 29 6 (2005) 1085-1093
21. Jacobi F., Wittchen H.U., Holting C., Hofler M., Pfister H., Muller N., and Lieb R. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol. Med. 34 4 (2004) 597-611
22. Keck M.E., Welt T., Muller M.B., Landgraf R., and Holsboer F. The high-affinity non-peptide CRH1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats. Pharmacopsychiatry 36 1 (2003) 27-31
23. Keck M.E., Wigger A., Welt T., Muller M.B., Gesing A., Reul J.M., Holsboer F., Landgraf R., and Neumann I.D. Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology 26 1 (2002) 94-105
24. Kendler K.S., Gatz M., Gardner C.O., and Pedersen N.L. A Swedish national twin study of lifetime major depression. Am. J. Psychiatry 163 1 (2006) 109-114
25. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., and Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289 23 (2003) 3095-3105
26. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., and Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62 6 (2005) 593-602
27. Kirschbaum C., Kudielka B.M., Gaab J., Schommer N.C., and Hellhammer D.H. Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitary-adrenal axis. Psychosom. Med. 61 2 (1999) 154-162
28. Kirschbaum C., Schommer N., Federenko I., Gaab J., Neumann O., Oellers M., Rohleder N., Untiedt A., Hanker J., Pirke K.M., and Hellhammer D.H. Short-term estradiol treatment enhances pituitary-adrenal axis and sympathetic responses to psychosocial stress in healthy young men. J. Clin. Endocrinol. Metab. 81 10 (1996) 3639-3643
29. Komesaroff P.A., Esler M., Clarke I.J., Fullerton M.J., and Funder J.W. Effects of estrogen and estrous cycle on glucocorticoid and catecholamine responses to stress in sheep. Am. J. Physiol. 275 4 Pt 1 (1998) E671-E678
30. Komesaroff P.A., Esler M.D., and Sudhir K. Estrogen supplementation attenuates glucocorticoid and catecholamine responses to mental stress in perimenopausal women. J. Clin. Endocrinol. Metab. 84 2 (1999) 606-610
31. Kunugi H., Ida I., Owashi T., Kimura M., Inoue Y., Nakagawa S., Yabana T., Urushibara T., Kanai R., Aihara M., Yuuki N., Otsubo T., Oshima A., Kudo K., Inoue T., Kitaichi Y., Shirakawa O., Isogawa K., Nagayama H., Kamijima K., Nanko S., Kanba S., Higuchi T., and Mikuni M. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology 31 1 (2006) 212-220
32. Kunzel H.E., Binder E.B., Nickel T., Ising M., Fuchs B., Majer M., Pfennig A., Ernst G., Kern N., Schmid D.A., Uhr M., Holsboer F., and Modell S. Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test. Neuropsychopharmacology 28 12 (2003) 2169-2178
33. Laakmann G., Hennig J., Baghai T., and Schule C. Influence of mirtazapine on salivary cortisol in depressed patients. Neuropsychobiology 47 1 (2003) 31-36
34. Magee J.A., Chang L.W., Stormo G.D., and Milbrandt J. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 147 1 (2006) 590-598
35. Majer M., Ising M., Kunzel H., Binder E.B., Holsboer F., Modell S., and Zihl J. Impaired divided attention predicts delayed response and risk to relapse in subjects with depressive disorders. Psychol. Med. 34 8 (2004) 1453-1463
36. Merali Z., Kent P., Du L., Hrdina P., Palkovits M., Faludi G., Poulter M.O., Bedard T., and Anisman H. Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biol. Psychiatry 59 7 (2006) 594-602
37. Nemeroff C.B. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol. Psychiatry 1 4 (1996) 336-342
38. Nemeroff C.B., Owens M.J., Bissette G., Andorn A.C., and Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry 45 6 (1988) 577-579
39. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., and Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226 4680 (1984) 1342-1344
40. Nickel T., Sonntag A., Schill J., Zobel A.W., Ackl N., Brunnauer A., Murck H., Ising M., Yassouridis A., Steiger A., Zihl J., and Holsboer F. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J. Clin. Psychopharmacol. 23 2 (2003) 155-168
41. Owashi T., Otsubo T., Oshima A., Nakagome K., Higuchi T., and Kamijima K. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression. Psychoneuroendocrinology 33 2 (2008) 152-161
42. Pariante C.M., and Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 49 5 (2001) 391-404
43. Pariante C.M., Pearce B.D., Pisell T.L., Owens M.J., and Miller A.H. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol. Pharmacol. 52 4 (1997) 571-581
44. Purba J.S., Hoogendijk W.J., Hofman M.A., and Swaab D.F. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatry 53 2 (1996) 137-143
45. Raadsheer F.C., Hoogendijk W.J., Stam F.C., Tilders F.J., and Swaab D.F. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60 4 (1994) 436-444
46. Redei E., Li L., Halasz I., McGivern R.F., and Aird F. Fast glucocorticoid feedback inhibition of ACTH secretion in the ovariectomized rat: effect of chronic estrogen and progesterone. Neuroendocrinology 60 2 (1994) 113-123
47. Reul J.M., Labeur M.S., Grigoriadis D.E., De Souza E.B., and Holsboer F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60 5 (1994) 509-519
48. Reul J.M., Stec I., Soder M., and Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133 1 (1993) 312-320
49. Roca C.A., Schmidt P.J., Altemus M., Deuster P., Danaceau M.A., Putnam K., and Rubinow D.R. Differential menstrual cycle regulation of hypothalamic-pituitary-adrenal axis in women with premenstrual syndrome and controls. J. Clin. Endocrinol. Metab. 88 7 (2003) 3057-3063
50. Roca C.A., Schmidt P.J., Deuster P.A., Danaceau M.A., Altemus M., Putnam K., Chrousos G.P., Nieman L.K., and Rubinow D.R. Sex-related differences in stimulated hypothalamic-pituitary-adrenal axis during induced gonadal suppression. J. Clin. Endocrinol. Metab. 90 7 (2005) 4224-4231
51. Rousseau G.G., Baxter J.D., and Tomkins G.M. Glucocorticoid receptors: relations between steroid binding and biological effects. J. Mol. Biol. 67 1 (1972) 99-115
52. Rubinow D.R., Roca C.A., Schmidt P.J., Danaceau M.A., Putnam K., Cizza G., Chrousos G., and Nieman L. Testosterone suppression of CRH-stimulated cortisol in men. Neuropsychopharmacology 30 10 (2005) 1906-1912
53. Scammell J.G., Denny W.B., Valentine D.L., and Smith D.F. Overexpression of the FK506-binding immunophilin FKBP51 is the common cause of glucocorticoid resistance in three New World primates. Gen. Comp. Endocrinol. 124 2 (2001) 152-165
54. Schmidt P.J., Berlin K.L., Danaceau M.A., Neeren A., Haq N.A., Roca C.A., and Rubinow D.R. The effects of pharmacologically induced hypogonadism on mood in healthy men. Arch. Gen. Psychiatry 61 10 (2004) 997-1004
55. Schule C., Baghai T., Zwanzger P., Ella R., Eser D., Padberg F., Moller H.J., and Rupprecht R. Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. Psychopharmacology (Berl) 166 3 (2003) 271-275
56. Sjoberg R.L., Nilsson K.W., Nordquist N., Ohrvik J., Leppert J., Lindstrom L., and Oreland L. Development of depression: sex and the interaction between environment and a promoter polymorphism of the serotonin transporter gene. Int. J. Neuropsychopharmacol. 9 4 (2006) 443-449
57. Steiner M., Dunn E., and Born L. Hormones and mood: from menarche to menopause and beyond. J. Affect. Disord. 74 1 (2003) 67-83
58. Su T.P., Pagliaro M., Schmidt P.J., Pickar D., Wolkowitz O., and Rubinow D.R. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 269 21 (1993) 2760-2764
59. Svec F. Differences in the interaction of RU 486 and ketoconazole with the second binding site of the glucocorticoid receptor. Endocrinology 123 4 (1988) 1902-1906
60. Tyrka A.R., Wier L., Price L.H., Ross N., Anderson G.M., Wilkinson C.W., and Carpenter L.L. Childhood parental loss and adult hypothalamic-pituitary-adrenal function. Biol. Psychiatry 63 12 (2008) 1147-1154
61. T'Sjoen G.G., De Vos S., Goemaere S., Van Pottelbergh I., Dierick M., Van Heeringen C., and Kaufman J.M. Sex steroid level, androgen receptor polymorphism, and depressive symptoms in healthy elderly men. J. Am. Geriatr. Soc. 53 4 (2005) 636-642
62. U M., Shen L., Oshida T., Miyauchi J., Yamada M., and Miyashita T. Identification of novel direct transcriptional targets of glucocorticoid receptor. Leukemia 18 11 (2004) 1850-1856
63. Vamvakopoulos N.C., and Chrousos G.P. Evidence of direct estrogenic regulation of human corticotropin-releasing hormone gene expression. Potential implications for the sexual dimophism of the stress response and immune/inflammatory reaction. J. Clin. Invest. 92 4 (1993) 1896-1902
64. Viau V. Functional cross-talk between the hypothalamic-pituitary-gonadal and -adrenal axes. J. Neuroendocrinol. 14 6 (2002) 506-513
65. Viau V., Chu A., Soriano L., and Dallman M.F. Independent and overlapping effects of corticosterone and testosterone on corticotropin-releasing hormone and arginine vasopressin mRNA expression in the paraventricular nucleus of the hypothalamus and stress-induced adrenocorticotropic hormone release. J. Neurosci. 19 15 (1999) 6684-6693
66. Viau V., and Meaney M.J. Variations in the hypothalamic-pituitary-adrenal response to stress during the estrous cycle in the rat. Endocrinology 129 5 (1991) 2503-2511
67. Viau V., and Meaney M.J. The inhibitory effect of testosterone on hypothalamic-pituitary-adrenal responses to stress is mediated by the medial preoptic area. J. Neurosci. 16 5 (1996) 1866-1876
68. Viau V., Soriano L., and Dallman M.F. Androgens alter corticotropin releasing hormone and arginine vasopressin mRNA within forebrain sites known to regulate activity in the hypothalamic-pituitary-adrenal axis. J. Neuroendocrinol. 13 5 (2001) 442-452
69. von Bardeleben U., Holsboer F., Stalla G.K., and Muller O.A. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci. 37 17 (1985) 1613-1618
70. Young E.A. Sex differences in response to exogenous corticosterone: a rat model of hypercortisolemia. Mol. Psychiatry 1 4 (1996) 313-319
71. Young E.A., and Altemus M. Puberty, ovarian steroids, and stress. Ann. N.Y. Acad. Sci. 1021 (2004) 124-133
72. Young E.A., Altemus M., Parkison V., and Shastry S. Effects of estrogen antagonists and agonists on the ACTH response to restraint stress in female rats. Neuropsychopharmacology 25 6 (2001) 881-891
73. Young E.A., and Ribeiro S.C. Sex differences in the ACTH response to 24H metyrapone in depression. Brain Res. 1126 1 (2006) 148-155
74. Young E.A., Ribeiro S.C., and Ye W. Sex differences in ACTH pulsatility following metyrapone blockade in patients with major depression. Psychoneuroendocrinology 32 5 (2007) 503-507
75. Yuuki N., Ida I., Oshima A., Kumano H., Takahashi K., Fukuda M., Oriuchi N., Endo K., Matsuda H., and Mikuni M. HPA axis normalization, estimated by DEX/CRH test, but less alteration on cerebral glucose metabolism in depressed patients receiving ECT after medication treatment failures. Acta Psychiatr. Scand. 112 4 (2005) 257-265
76. Zobel A.W., Nickel T., Sonntag A., Uhr M., Holsboer F., and Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. J. Psychiatr. Res. 35 2 (2001) 83-94
77. Zobel A.W., Yassouridis A., Frieboes R.M., and Holsboer F. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am. J. Psychiatry 156 6 (1999) 949-951
78. Zubenko G.S., Hughes III H.B., Maher B.S., Stiffler J.S., Zubenko W.N., and Marazita M.L. Genetic linkage of region containing the CREB1 gene to depressive disorders in women from families with recurrent, early onset, major depression. Am. J. Med. Genet. 114 8 (2002) 980-987
79. Zubenko G.S., Hughes III H.B., Stiffler J.S., Brechbiel A., Zubenko W.N., Maher B.S., and Marazita M.L. Sequence variations in CREB1 cosegregate with depressive disorders in women. Mol. Psychiatry 8 6 (2003) 611-618